Learn More
Invitrogen™ Cytomegalovirus p65 Monoclonal Antibody (CMV-224)

Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA533319
Description
Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, CMV is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of CMV disease. An indicator of active CMV infection is needed to facilitate the diagnosis of CMV disease in patients with AIDS or HIV infection. CMV p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.Chemical Identifiers
| Cytomegalovirus p65 | |
| 100 μg/mL | |
| ELISA, Flow Cytometry, Immunohistochemistry (Frozen) | |
| Unconjugated | |
| Mouse | |
| RUO | |
| PBS with 0.02% sodium azide | |
| Recombinant CMV-p65 protein. | |
| Antibody |
| CMV-224 | |
| 4°C, do not freeze | |
| Monoclonal | |
| Liquid | |
| IgG1 κ | |
| Virus | |
| CMV; CMV p65 | |
| Primary | |
| Protein A/G |
Specifications
| Cytomegalovirus p65 | |
| Monoclonal | |
| 100 μg/mL | |
| PBS with 0.02% sodium azide | |
| Mouse | |
| Protein A/G | |
| RUO | |
| Virus | |
| Antibody | |
| IgG1 κ |
| ELISA, Flow Cytometry, Immunohistochemistry (Frozen) | |
| CMV-224 | |
| Unconjugated | |
| CMV; CMV p65 | |
| Recombinant CMV-p65 protein. | |
| 100 μg | |
| Primary | |
| 4°C, do not freeze | |
| Liquid |